Skip to main content

Information for Health Professionals

This section provides resources for healthcare personnel who provide immunization services.

It's Federal Law - You Must Use Vaccine Information Statements (CDC web site) every time you give a vaccine.

What's New     

HPV Resources
HPV Champion Toolkit
(AAP website)
Talking to Your Parents about the HPV Vaccine
(AAP website)
Additional guidance for providers regarding 9-valent HPV vaccine use among persons who previously received 2-valent HPV or 4-valent HPV vaccine.
Meningococcal group B (MenB) vaccines now available through the VFC Program for ages 16–18 years (CDC web site) This includes adolescents and young adults who do not have a condition or are not in a situation which increases their risk for serogroup B meningococcal disease.
Meningococcal B Recommendations for Persons Aged ≥10 Years at Increased Risk for Serogroup B Meningococcal Disease (CDC  web site)

Recommended Immunization Schedules - United States 2017

ACIP Recommendations (CDC web site) 

Questions and Answers on the right are adapted from "Ask the Experts: CDC answers questions"  acquired on 2-28-2013.  We thank the Immunization Action Coalition.

Free Online Immunization Training

Satellite broadcasts and web casts - Available on DVD and as archived web casts. Continuing education available (CME, CNE, CEU, CECH for Health Educators).

Additional Free Online Continuing Education Resources for Vaccine Providers

CE Credit for Physicians

CE Credit for Nurses

Important Information

For Vaccine Providers

The Pink Book and other Resources

Vaccine Storage and Handling

 Clinic Operations

Screening for Contraindications

Every person who administers vaccines should screen every patient for contraindications and precautions before giving vaccines.  

Effective screening is key to preventing serious adverse events and is not difficult or complicated. Screening can be accomplished with just a few questions (See the screening forms which follow).

The "Contraindications and Precautions" section in the General Recommendations (CDC web site), pages 40 through 43, describes valid and invalid contraindications and precautions.

More specific information on contraindications and precautions is available in vaccine-specific ACIP recommendations.

Vaccine Information Statements – Required by Federal Regulation

Vaccine Administration - Essential Resources for Your Clinic

Vaccine Safety - Healthcare Personnel Responsibilities to Ensure Vaccine Safety

  • Store vaccines properly.
  • Distribute Vaccine Information Statements to parents or vaccine recipients prior to administration of each dose of vaccine and answer all patient and parent questions.
  • Administer vaccines correctly including proper dose, route, site, and needle size.
  • Screen patients for and observe valid precautions and contraindications.
  • Follow current recommended immunization schedules for children, adolescents and adults, including proper timing and spacing of vaccine doses.
  • Manage vaccine side effects using your best clinical judgment.
  • Have procedures in place and be prepared for emergency care of a person who experiences an anaphylactic reaction.
  • Report suspected side effects to the Vaccine Adverse Event Reporting System (VAERS).
  • Follow federal requirements for recording vaccines administered.

Resources for Conversations with Parents 

2016 Editions
January 2016 Oklahoma Immunization Update 
February 2016 Oklahoma Immunization Update 
March 2016 Oklahoma Immunization Update
April 2016 Oklahoma Immunization Update 

For previous issues of the Oklahoma Immunization Update contact the Immunization Service at (405) 426-8580.

Frequently Asked Questions
Q: What are the new ACIP recommendations for vaccinating pregnant women with Tdap?
A: The new ACIP recommendations are that pregnant women receive Tdap vaccine during each pregnancy, even if they have received Tdap previously. Women who have never received Tdap and who do not receive it during pregnancy should receive it immediately postpartum.

Q: If a woman did not receive Tdap during pregnancy, and it is uncertain whether she received a dose of Tdap prior to her pregnancy, should she receive a dose of Tdap postpartum?
A: Yes. If there is no written documentation that she received a dose of Tdap prior to or during pregnancy, a dose of Tdap should be administered to her immediately postpartum.

Q: A 7-year-old who needed a tetanus shot for wound management came into our emergency department. My question is, if a child has received the complete 5-dose series of DTaP but has never had Tdap, should the child receive Tdap or Td for wound management?
A: Neither. A child who has completed 5 doses of DTaP has by definition received the fifth dose on or after his/her fourth birthday. In this child's case, it has been less than four years since receipt of the complete series, so the child does not need either Tdap or Td. The child is fully vaccinated against tetanus according to CDC tetanus wound management guidelines.

Q: What are the new ACIP recommendations for use of MenHibrix, the new combination meningococcal Groups C and Y and Haemophilus influenzae type b vaccine?
A: Licensed in June 2012, MenHibrix (Hib-MenCY; GSK) is a vaccine indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroups C and Y and Haemophilus influenzae type b. This vaccine does not protect against meningococcal serogroups A, B, and W135. In October 2012, ACIP voted to recommend that infants at increased risk for meningococcal disease be vaccinated with 4 doses of Hib-MenCY at age 2, 4, 6, and 12 through 15 months. This includes infants with recognized persistent complement pathway deficiencies and infants who have anatomic or functional asplenia, including sickle cell disease. You can find this in footnote #13 of the "Recommended Immunization Schedule for Persons Aged 0 Through 18 Years - United States, 2013". Hib-MenCY can be used in infants age 2 through 18 months who live in communities with serogroup C and Y meningococcal disease outbreaks.

Related Topics
Back to Top